Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption

Stock Track03-21

ARS Pharmaceuticals Inc (SPRY) saw its stock price plummet 5.59% in pre-market trading on Friday following the release of its fourth quarter and full year 2024 financial results. The decline reflects investor concerns over the slower-than-anticipated adoption of the company's flagship product, neffy, a needle-free epinephrine nasal spray for severe allergic reactions.

During the earnings call, ARS Pharmaceuticals reported $7.3 million in neffy sales for the full year 2024, which fell short of market expectations. The company cited challenges with prior authorizations as a significant hurdle in driving initial prescriptions. Despite these obstacles, ARS Pharmaceuticals highlighted progress in securing payer coverage, with a goal of reaching 80% unrestricted commercial coverage by early summer 2025.

Looking ahead, ARS Pharmaceuticals outlined plans to accelerate adoption, including the launch of a direct-to-consumer advertising campaign in May 2025 and the introduction of a 1mg dose for children. The company also expects the upcoming availability of real-world data from its neffy Experience Program to boost physician confidence. However, investors appear to be taking a cautious stance, waiting to see if these initiatives will translate into significant sales growth in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132725662?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-21 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132725662","market":"us","top_or_hot":-1,"title":"Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption","media":"Stock Track","content":"<p>ARS Pharmaceuticals Inc (SPRY) saw its stock price plummet 5.59% in pre-market trading on Friday following the release of its fourth quarter and full year 2024 financial results. The decline reflects investor concerns over the slower-than-anticipated adoption of the company's flagship product, neffy, a needle-free epinephrine nasal spray for severe allergic reactions.</p>\n\n<p>During the earnings call, ARS Pharmaceuticals reported $7.3 million in neffy sales for the full year 2024, which fell short of market expectations. The company cited challenges with prior authorizations as a significant hurdle in driving initial prescriptions. Despite these obstacles, ARS Pharmaceuticals highlighted progress in securing payer coverage, with a goal of reaching 80% unrestricted commercial coverage by early summer 2025.</p>\n\n<p>Looking ahead, ARS Pharmaceuticals outlined plans to accelerate adoption, including the launch of a direct-to-consumer advertising campaign in May 2025 and the introduction of a 1mg dose for children. The company also expects the upcoming availability of real-world data from its neffy Experience Program to boost physician confidence. However, investors appear to be taking a cautious stance, waiting to see if these initiatives will translate into significant sales growth in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-21 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ARS Pharmaceuticals Inc (SPRY) saw its stock price plummet 5.59% in pre-market trading on Friday following the release of its fourth quarter and full year 2024 financial results. The decline reflects investor concerns over the slower-than-anticipated adoption of the company's flagship product, neffy, a needle-free epinephrine nasal spray for severe allergic reactions.</p>\n\n<p>During the earnings call, ARS Pharmaceuticals reported $7.3 million in neffy sales for the full year 2024, which fell short of market expectations. The company cited challenges with prior authorizations as a significant hurdle in driving initial prescriptions. Despite these obstacles, ARS Pharmaceuticals highlighted progress in securing payer coverage, with a goal of reaching 80% unrestricted commercial coverage by early summer 2025.</p>\n\n<p>Looking ahead, ARS Pharmaceuticals outlined plans to accelerate adoption, including the launch of a direct-to-consumer advertising campaign in May 2025 and the introduction of a 1mg dose for children. The company also expects the upcoming availability of real-world data from its neffy Experience Program to boost physician confidence. However, investors appear to be taking a cautious stance, waiting to see if these initiatives will translate into significant sales growth in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRY","symbol_name":"ARS PHARMACEUTICALS INC","start_time":0,"source_url":"","article_id":"1132725662","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132725662","pubTimestamp":1742563968,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ARS Pharmaceuticals Inc  saw its stock price plummet 5.59% in pre-market trading on Friday following the release of its fourth quarter and full year 2024 financial results. The decline reflects investor concerns over the slower-than-anticipated adoption of the company's flagship product, neffy, a needle-free epinephrine nasal spray for severe allergic reactions.During the earnings call, ARS Pharmaceuticals reported $7.3 million in neffy sales for the full year 2024, which fell short of market ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPRY":"ARS PHARMACEUTICALS INC"},"translate_title":"由于第四季度收益显示Neffy采用速度慢于预期，ARS Pharmaceuticals股价暴跌5.59%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":1},"content_text":"ARS Pharmaceuticals Inc (SPRY) saw its stock price plummet 5.59% in pre-market trading on Friday following the release of its fourth quarter and full year 2024 financial results. The decline reflects investor concerns over the slower-than-anticipated adoption of the company's flagship product, neffy, a needle-free epinephrine nasal spray for severe allergic reactions.\nDuring the earnings call, ARS Pharmaceuticals reported $7.3 million in neffy sales for the full year 2024, which fell short of market expectations. The company cited challenges with prior authorizations as a significant hurdle in driving initial prescriptions. Despite these obstacles, ARS Pharmaceuticals highlighted progress in securing payer coverage, with a goal of reaching 80% unrestricted commercial coverage by early summer 2025.\nLooking ahead, ARS Pharmaceuticals outlined plans to accelerate adoption, including the launch of a direct-to-consumer advertising campaign in May 2025 and the introduction of a 1mg dose for children. The company also expects the upcoming availability of real-world data from its neffy Experience Program to boost physician confidence. However, investors appear to be taking a cautious stance, waiting to see if these initiatives will translate into significant sales growth in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132725662"}